Therapeutics Company Announces Notice of Allowance For Major Patent Over Metabolic Disease Program

BioRestorative Therapies, Inc. (BioRestorative or BRTX), a company specializing in stem cell-based therapies, has announced that it received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135. This patent pertains to the company's allogeneic, off-the-shelf ThermoStem® platform, a crucial aspect of its metabolic disease program. $Biorestorative Therapies (BRTX.US)$